The use of IL-17 inhibitors in patients with psoriasis was associated with an increased risk for fungal infections when compared with other biologics.

The anti-IL-23 monoclonal antibody, called picankibart, was shown to clear or nearly clear all lesions after 16 weeks among 48.2% of the 82 participating Chinese patients that were classified as ...

Thomas Bieber, University of Bonn, Germany, wasted no time in welcoming his colleagues from around the world to the ...

A literature search performed in 2009 showed reports of more than 100 adults developing psoriasis or a psoriasiform rash following anti-TNF therapy, with more than 60 developing new-onset lesions ...

Investigators aimed to highlight aspects that may predict the time to relapse among patients with psoriasis who discontinued use of biologic therapy.

Not everyone with psoriasis develops psoriatic arthritis ... “The initial treatments are the same for both,” says Bauer, noting that tumor necrosis factor (TNF) inhibitors work well for both types of ...

Innovent Biologics (IVBXF) announced the latest clinical results of a multicenter, open-label Phase 2 study of picankibart, a recombinant ...

Sep. 26, 2024 — Scientists believe the hormone hepcidin, when produced in the skin, may be the root cause of psoriasis -- a chronic and sometimes debilitating skin disease that affects 2-3% of ...

High threshold clinical responses (Investigator’s Global Assessment Score 0 or 1, and Psoriasis Area and Severity Index ... while IZAR-2 will enroll patients with an inadequate response to tumor ...

Nail psoriasis can make it hard to do certain tasks that involve the fingernails, like grasping small objects. Intact fingernails and toenails also help to protect the fingers and toes ...

Psoriasis is an autoimmune disease that causes your body to overproduce skin cells. It most commonly causes thick, raised skin plaques to develop on your body. When psoriasis affects your nails ...

SLK did well in all other secondary endpoints, including Psoriasis Area and Severity ... Major approved drugs include Tumor Necrosis Factor (TNF) Inhibitors Adalimumab (Humira), Etanercept ...